Advances in gene expression and molecular profiling have clarified that breast cancer is not a single disease entity, but a heterogeneous disease with multiple subtypes. Breast cancers can now be categorized into the luminal subtypes, which express estrogen receptors (ERs), the human epidermal growth factor receptor 2 (HER2)-positive subtypes, which express ERBB2, and the basal subtypes, which tend to be negative for ERs and ERBB2 expression; [1] [2] [3] each subtype is associated with a different prognosis. As a result, the adjuvant treatment of breast cancer has also evolved to reflect the heterogeneous nature of the disease. This evolution of treatment options illustrates the complexity of adjuvant therapy selection for patients with newly diagnosed breast cancer. This article will highlight the evolution of treatments and risk stratification models over time and introduce possible developments for the future of breast cancer therapy.
trial (n=10,500) is prospectively investigating the role of the OncotypeDX assay to assess which patients with early-stage breast cancer and an intermediate RS would be more likely to benefit from chemotherapy and to reduce the use of chemotherapy in those who are unlikely to benefit from it (NCT 00310180). A similar study, the Microarray in Node-Negative Disease May Avoid Chemotherapy (MINDACT) trial (n=6,000), is prospectively investigating the role of the 70-gene MammaPrint assay in order to assess the best individual therapy (endocrine therapy with or without chemotherapy) in patients with node-negative, ER-positive breast cancer. These two geneexpression profiling assays have outperformed standard clinicopathological risk assessment models in predicting risk for distant metastases and OS. 5, 6 Endocrine Therapy with Anti-estrogens
Tamoxifen
Among the first molecular markers targeted for individualized therapy were the ERs (see Table 1 ). The selective ER modulator tamoxifen was first evaluated in lymph-node-negative, ER-positive breast cancers in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial, which randomized patients to tamoxifen 10mg twice daily or placebo. 7 Over four years of follow-up, there was a significant improvement in disease-free survival (DFS) among all subgroups of patients. This benefit persisted over 15 years of follow-up, with a documented improvement in recurrence-free survival (RFS) of 42% (13% absolute benefit) and OS of 20% (6% absolute benefit). 8 Although the optimal duration of treatment was initially unknown, patients treated with tamoxifen for more than five years experienced a lower DFS, RFS, and OS than those whose treatment was discontinued at five years. 9 The occurrence of tamoxifen resistance and clinically significant side effects such as thromboembolic disease, hot flashes, or uterine malignancy prompted a search for alternative agents in the adjuvant setting.
Aromatase Inhibitors
Aromatase inhibitors, which prevent the peripheral formation of estrogen within adipose tissue and have been effective in postmenopausal women with advanced, hormone-receptor-positive, tamoxifen-resistant tumors, [10] [11] [12] [13] are among the newer agents to be tested. (3% absolute benefit) compared with tamoxifen. 16 The role of aromatase inhibitors given sequentially after tamoxifen was evaluated in the Intergroup Exemestane Study (IES) and the MA.17 study. Patients enrolled in the IES trial were randomized to switch to exemestane after two to three years of tamoxifen therapy or complete the original five years with tamoxifen. With five years of follow-up data, patients changing therapy to exemestane experienced an improvement in DFS by 24% (3.3% absolute benefit), with little change in OS. 17 The MA.17 trial randomized patients completing five years of adjuvant tamoxifen to five years of either letrozole or placebo. 18 The trial was stopped early when a pre-planned analysis found an improvement in DFS among those patients randomized to letrozole. OS was the same in both arms, but lymphnode-positive patients in the letrozole arm had statistically significantly better OS.
Taken together, these results suggest an improvement in outcomes, particularly DFS, among post-menopausal women with hormonereceptor-positive breast cancers assigned to take aromatase inhibitors rather than tamoxifen for adjuvant hormonal therapy or aromatase inhibitors following tamoxifen for extended adjuvant hormonal therapy.
Although aromatase inhibitors reduce bone mineral density and increase fracture risk, 19, 20 these risks are reduced by the concomitant use of bisphosphonates. 21 Consequently, the use of aromatase inhibitors in the adjuvant setting has become standard practice among post-menopausal women. Aromatase inhibitors are not indicated for Breast Cancer 
Chemotherapy
The role of adjuvant chemotherapy (see Table 2 ) for patients with node-negative breast cancer was first evaluated in the NSABP B-13 trial, which examined the effect of sequential methotrexate and fluorouracil (5FU) followed by leucovorin versus surgery alone in ERnegative breast cancer patients. After four years of follow-up, an improvement in DFS was noted, 24 an effect that persisted through eight years of follow-up, where DFS improved from 59 to 74% (p<0.001). 25 A similar effect was observed among ER-negative, nodenegative patients assigned to post-operative chemotherapy with cyclophosphamide, methotrexate, and 5FU (CMF) versus surgery alone in the NSABP B-19 trial, where DFS improved from 73 to 82% (p<0.001) but OS improved only minimally.
The addition of CMF chemotherapy to tamoxifen in ER-positive, nodenegative patients was documented in the B-20 trial, which randomized patients to CMF plus tamoxifen or tamoxifen alone. The addition of chemotherapy to hormone therapy improved the RFS by 48% (10% absolute benefit) and OS by 22% (4% absolute benefit) up to 12 years after treatment. 8 The effect of chemotherapy on tamoxifenresponsive breast cancer patients with node-positive disease was also confirmed in the B-16 trial, which documented an improvement in DFS from 67 to 84% (p=0.0004) in patients ≥50 years of age treated with doxorubicin + cyclophosphamide (AC) and tamoxifen versus tamoxifen alone, as well with improvements in distant DFS and OS. 26 The relative efficacy of standard CMF chemotherapy, given initially over 12 months and subsequently over six months, was compared with the shorter two-month-long anthracycline-containing regimen of AC chemotherapy in the B-15 protocol, which randomized patients with node-positive disease unresponsive to tamoxifen. The 63-day AC protocol was as effective as the 154-day CMF protocol in DFS and OS, with the CMF-treated patients requiring more office visits, antinausea therapy, and experiencing similar degrees of alopecia.
Therefore, the AC regimen was considered preferable due to a shorter duration of therapy, similar toxicities, and a similar degree of benefit. 27 Several other studies have examined the role of various anthracycline-containing regimens compared with standard CMF;
all showed no significant differences in DFS or OS. [28] [29] [30] However, a phase II study of intensive cyclophosphamide, epirubicin, and 5FU
(CEF) versus CMF for six months documented an improvement in DFS from 53 to 63% (p=0.009) and OS from 70 to 77% (p=0.03), although CEF was associated with a higher rate of febrile neutropenia and acute leukemia. 31 The addition of a taxane to chemotherapy regimens was first investigated by the addition of paclitaxel for four cycles following four cycles of AC chemotherapy (with three doxorubicin dose escalation arms of 60, 75, and 90mg/m 2 ) in women with node-positive disease in the Cancer and Leukemia Group B (CALGB) 9344 trial. Although the escalation of the dose of doxorubicin did not affect outcomes, the addition of paclitaxel improved DFS (65-70%) and OS (77-80%) at five years, with minimal additional toxicity. The benefit of paclitaxel was most significant for those patients with ER-negative tumors rather than ER-positive tumors (most of whom were also treated with tamoxifen). 32 In 2005, the NSABP B-28 trial reported similar findings, with the addition of paclitaxel after four cycles of AC improving DFS by 4% (absolute benefit) with a small but non-significant improvement in OS. 33 The optimal taxane choice and dosing regimen was examined in a trial of paclitaxel or docetaxel every one or three weeks following standard AC chemotherapy. Compared with standard paclitaxel every three weeks, weekly paclitaxel was the most effective at improving DFS (76.9-81.5%) and OS (86.5-89.7%) at five years, although this regimen was also more likely to cause grade 2-4 neuropathy. 34 The role of taxanes in adjuvant chemotherapy has expanded after the US Oncology (USO) trial USO9735 examined the role of four cycles of docetaxel and cyclophosphamide (TC) in early-stage invasive breast Table 3 ). The NSABP B-31 trial and the North Central Cancer Treatment Group (NCCTG) N9831 trials were both designed to test the effects of trastuzumab when added to a standard regimen of AC chemotherapy followed by paclitaxel in patients with HER2-positive disease. Patients were randomized to complete the standard chemotherapy approach with or without the addition of trastuzumab for one year. When the results of these studies were combined, the addition of trastuzumab reduced the risk for recurrence by 52% and improved DFS by 18.2% (absolute benefit) at four years. The relative risk for death also decreased by 33% (4.8% absolute benefit) with the addition of trastuzumab. 39 However, the use of adjuvant trastuzumab was also associated with a small (0.4-3.8%) but significant risk for congestive heart failure. 
Future Directions
The success of specifically targeted therapy with trastuzumab has Bevacizumab, a monoclonal antibody designed to inhibit the vascular endothelial growth factor (VEGF), which is necessary for tumor angiogenesis, has been found to be beneficial in several solid tumors, including metastatic breast cancer, 46 and is currently being evaluated in several trials in the adjuvant breast cancer setting. These trials include the Eastern Co-operative Oncology Group (ECOG)-5103
Breast Cancer Lastly, the concept of personalized therapy is being advanced by the understanding that pharmacogenetics (PGs) play an important role in the efficacy of any therapy. Emerging data show that patients respond differently to tamoxifen depending on the PG make-up. 48 In the future, more precise tailoring of adjuvant therapy may be possible based on a PG profile.
Conclusion
The goals of adjuvant therapy in breast cancer are to reduce the risk for recurrence and improve survival with the least acute and/or chronic toxicity possible. 
